MS patients may feel depression as their Monoclonal Antibody Treatment “wears off”
While the “feel good effect” has long been associated with the use of the monoclonal antibody Natalizumab, there is now evidence that the wearing-off of this and other monoclonal antibodies is associated with depression. In fact, more than half of MS patients treated with the monoclonal antibodies Ocrevus, Rituxan, and Natalizumab who were surveyed reported […]
MS patients may feel depression as their Monoclonal Antibody Treatment “wears off” Read More »









